{
  "id": "6027446d1cb411341a0000dd",
  "type": "yesno",
  "question": "Does trimetazidine protect from myocardial injury after percutaneous coronary intervention?",
  "ideal_answer": "Oral trimetazidine 35 mg twice daily over several years in patients receiving optimal medical therapy, after successful PCI, does not influence the recurrence of angina or the outcome; these findings should be taken into account when considering the place of trimetazidine in clinical practice.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32877651"
  ],
  "snippets": [
    {
      "text": "After a median follow-up of 47\u00b75 months (IQR 42\u00b73-53\u00b73), incidence of primary endpoint events was not significantly different between the trimetazidine group (700 [23\u00b73%] patients) and the placebo group (714 [23\u00b77%]; hazard ratio 0\u00b798 [95% CI 0\u00b788-1\u00b709], p=0\u00b773). When analysed individually, there were no significant differences in the incidence of the components of the primary endpoint between the treatment groups. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32877651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Our results show that the routine use of oral trimetazidine 35 mg twice daily over several years in patients receiving optimal medical therapy, after successful PCI, does not influence the recurrence of angina or the outcome; these findings should be taken into account when considering the place of trimetazidine in clinical practice. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32877651",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}